SpringWorks Therapeutics Email Format

Biotechnology ResearchConnecticut, United States201-500 Employees

SpringWorks Therapeutics is a commercial-stage biopharmaceutical company focused on developing and delivering medicines for patients with rare tumors. It operates as part of Merck KGaA and is based in Stamford, Connecticut. The company has commercialized therapies that have received FDA and EC approval for desmoid tumors in adults, and for both adults and children with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

Its target market includes patients with rare tumors and the clinicians who treat them, with a focus on delivering therapies that address unmet medical needs in this area. SpringWorks positions itself within the biotechnology research sector as a company pursuing answers for rare-tumor patients, emphasizing scientific progress and urgency in its work. In early 2025, the company expanded its collaboration ecosystem with industry partners, including a global license agreement with Rappta Therapeutics to advance a preclinical program targeting PP2A.

Sign up for free to view info

Company overview Employee directory